Skip to content

Piedmont Aging, Cognition & Exercise Study-2

A Randomized Controlled Trial to Examine the Effects of Aerobic Exercise on Cognition and Aging-related Biomarkers for Adults With Prediabetes and Mild Cognitive Impairment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02312843
Acronym
PACE-2
Enrollment
33
Registered
2014-12-09
Start date
2013-03-31
Completion date
2017-04-30
Last updated
2018-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment, Prediabetes

Keywords

Mild Cognitive Impairment, Cognitive disorders, Prediabetes, Exercise

Brief summary

The purpose of this research study is to examine the effects of high and low intensity exercise for those with mild memory loss and pre-diabetes. The investigators will also examine the effects of this exercise on certain proteins and hormones in body fluids, and on brain structure and function using magnetic resonance imaging (MRI). Recent studies indicate that exercise improves memory and thinking abilities for adults with mild memory loss OR pre-diabetes. This study examines the effects of exercise on people with mild memory loss AND pre-diabetes.

Interventions

BEHAVIORALExercise/Aerobic
BEHAVIORALExercise/Stretching

Sponsors

American Diabetes Association
CollaboratorOTHER
Wake Forest University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 89 Years
Healthy volunteers
Yes

Inclusion criteria

* 50 years or older * Mild memory concerns * In good health * Not taking diabetes medications * Not currently exercising

Exclusion criteria

* Significant neurologic disease that might affect cognition, such as AD, stroke, Parkinson's disease, multiple sclerosis, or severe head injury with loss of consciousness \> 30 min or with permanent neurologic sequelae; * Significant medical illness or organ failure, such as: * Liver disease: history of hepatitis or hepatic failure * Significant elevations in liver function tests: lab values more than 2.5 times the upper limit of normal * Kidney disease known history of kidney failure. * Uncontrolled hypertension * Cardiovascular disease, defined as: any acute cardiovascular abnormality, such as new or unstable angina, uncontrolled irregular heart beat (treated a-fib and occasional PVC's are OK) or symptomatic heart failure, acute shortness of breath for any reason, or clinically significant edema, is an exclusion. History in the last year of myocardial infarction, angina, coronary artery angioplasty, bypass grafting, pacemaker insertion, STENT placement, postural hypotension, transient ischemic attack, or carotid artery surgery. * Chronic lung disease, such as: COPD/emphysema * Hemoglobin A1c levels that fall outside the range of 5.7-6.4%; If 2-h OGTT glucose values 220 mg/dL and hemoglobin A1c levels meet inclusion criteria (5.7-6.4%), then PCP written indication that no pharmacologic intervention for type 2 diabetes is needed at present will be required for continued study participation. * Current use of anti-psychotic, anti-convulsant, anxiolytic, or sedative medication; * Current use of any cognition-enhancing medication, including experimental medications within the past 60 days; * Current or previous use of hypoglycemic agents or insulin (except during pregnacy); diabetics previously on oral agents but have been off of them for \> 1 year are ok pending PI and study physician approval. * Musculoskeletal impairment sufficient to interfere with study participation

Design outcomes

Primary

MeasureTime frameDescription
Change in cognitive performance from baseline following 6 month of high or low intensity exercise regimen2 assessments, one before and one after 6 months of exerciseThe cognitive variables identified above, by domain, will be subjected to separate treatment group X treatment month (3, 6) multivariate analyses of covariance (MANCOVA), with baseline scores and age serving as covariates. When the MANCOVA proves significant, separate post-hoc analysis of covariance (ANCOVA) will be conducted on the relevant dependent variables. Cognitive tests include measures of executive function and working memory.

Secondary

MeasureTime frameDescription
Change from baseline in blood sugar concentration and cerebrospinal fluid glucose measures during an oral glucose tolerance test following 6 months of high or low intensity exercise3 Oral glucose tolerance tests over a 6 month period; 2 lumbar punctures, one before and one after the 6 month exercise regimenMultiple regression and correlational (MRC) analyses will be conducted to evaluate whether treatment-induced change in insulin sensitivity and in other blood and cerebrospinal fluid biomarkers predict cognitive performance among subjects in the aerobic group.

Other

MeasureTime frameDescription
Change from baseline in brain network connectivity using brain imaging2 brain scans over a 6 month period, one before and one after the 6 month exercise regimenWhole-brain averages will be computed, reflecting characteristics of the entire system. Whole-brain averages will be compared with random networks generated with the same node number and degree,48 and will be compared between intervention groups using general linear regression models. Regions of interest (hippocampus, posterior cingulate/precuneus, prefrontal cortex) will be extracted using WFU Pickatlas and regional degree, Eglob, or Eloc will be compared between groups using the general linear model.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026